Evidence map›Paper›PMID 38948907›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2024

COPD Exacerbations Before and During COVID-19 in France, Germany, Italy, the UK and the US.

Fernando J Martinez, Alberto Papi, Tobias Welte, Dave Singh, Dmitry V Galkin, Alessandro Guasconi, Stefania Pirondi, George Georges, Joseph Imperato, Ruben Hermans

Abstract read
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fernando J MartinezWeill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA.ORCID 0000-0002-2412-3182
Alberto PapiResearch Center on Asthma and COPD, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.ORCID 0000-0002-6924-4500
Tobias WeltePneumonology and Infectiology, Member of the German Center of Lung Research, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-9947-7356
Dave SinghMedicines Evaluations Unit, University of Manchester, Manchester University Foundation Hospitals Trust, Manchester, UK.
Dmitry V GalkinGlobal Clinical Development, Chiesi USA, Cary, NC, USA.
Alessandro GuasconiGlobal Clinical Development, Chiesi Farmaceutici, S.p.A, Parma, Italy.
Stefania PirondiGlobal Clinical Development, Chiesi Farmaceutici, S.p.A, Parma, Italy.
George GeorgesGlobal Clinical Development, Chiesi Farmaceutici, S.p.A, Parma, Italy.ORCID 0000-0002-0303-2273
Joseph ImperatoMedical Affairs, IQVIA Inc, New York, NY, USA.
Ruben HermansMedical Affairs, IQVIA Inc, London, UK.

Funding

Agenzia Italiana del Farmaco (AIFA), and SanofiAstraZeneca, Chiesi Farmaceutici S.p.A., GSK and Sanofi/RegeneronBerlin-ChemieChiesi Farmaceutici S.p.A.
6 · The paper itself

Abstract

Background: Exacerbations of chronic obstructive pulmonary disease (COPD) were reported less frequently during the COVID-19 pandemic. We report real-world data on COPD exacerbation rates before and during this pandemic. Methods: Exacerbation patterns were analysed using electronic medical records or claims data of patients with COPD before (2017-2019) and during the COVID-19 pandemic (2020 through early 2022) in France, Germany, Italy, the United Kingdom and the United States. Data from each country were analysed separately. The proportions of patients with COPD receiving maintenance treatment were also estimated. Results: The proportion of patients with exacerbations fell 45-78% across five countries in 2020 versus 2019. Exacerbation rates in most countries were reduced by >50% in 2020 compared with 2019. The proportions of patients with an exacerbation increased in most countries in 2021. Across each country, seasonal exacerbation increases seen during autumn and winter in pre-pandemic years were absent during the first year of the pandemic. The percentage of patients filling COPD prescriptions across each country increased by 4.53-22.13% in 2019 to 9.94-34.17% in 2021. Conclusion: Early, steep declines in exacerbation rates occurred in 2020 versus 2019 across all five countries and were accompanied by a loss of the seasonal pattern of exacerbation.

Indexed as

COVID-19Disease ProgressionPulmonary Disease, Chronic ObstructiveAgedFemaleFranceHumansItalyMaleMiddle AgedPandemicsSARS-CoV-2SeasonsTime FactorsUnited KingdomUnited Stateschronic obstructive pulmonary diseaseCOPD exacerbationCOVID-19electronic health recordsreal-world study

Identifiers

PMID38948907
PMCPMC11214557

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.